Susquehanna International Group’s Abeona Therapeutics ABEO Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $1.94M | Sell |
432,370
-268,918
| -38% | -$1.34M | ﹤0.01% | 6263 |
|
|
2025
Q4 | $3.7M | Buy |
+701,288
| New | +$3.53M | ﹤0.01% | 4527 |
|
|
2025
Q3 | – | Sell |
-55,122
| Closed | -$350K | – | 12232 |
|
|
2025
Q2 | $313K | Sell |
55,122
-705,946
| -93% | -$4.02M | ﹤0.01% | 10240 |
|
|
2025
Q1 | $3.62M | Buy |
761,068
+182,874
| +32% | +$995K | ﹤0.01% | 4284 |
|
|
2024
Q4 | $3.22M | Buy |
578,194
+510,954
| +760% | +$3.14M | ﹤0.01% | 4354 |
|
|
2024
Q3 | $425K | Buy |
67,240
+19,677
| +41% | +$103K | ﹤0.01% | 8862 |
|
|
2024
Q2 | $202K | Buy |
47,563
+20,097
| +73% | +$103K | ﹤0.01% | 10344 |
|
|
2024
Q1 | $199K | Sell |
27,466
-13,694
| -33% | -$86.8K | ﹤0.01% | 10601 |
|
|
2023
Q4 | $206K | Sell |
41,160
-27,717
| -40% | -$122K | ﹤0.01% | 10620 |
|
|
2023
Q3 | $290K | Buy |
+68,877
| New | +$261K | ﹤0.01% | 9419 |
|
|
2022
Q1 | – | Sell |
-447
| Closed | -$4K | – | 12873 |
|
|
2021
Q4 | $4K | Buy |
+447
| New | +$8.21K | ﹤0.01% | 12996 |
|
|
2021
Q3 | – | Sell |
-4,507
| Closed | -$144K | – | 12639 |
|
|
2021
Q2 | $176K | Buy |
4,507
+772
| +21% | +$31.5K | ﹤0.01% | 11721 |
|
|
2021
Q1 | $175K | Sell |
3,735
-526
| -12% | -$29K | ﹤0.01% | 11531 |
|
|
2020
Q4 | $167K | Buy |
4,261
+2,817
| +195% | +$96K | ﹤0.01% | 10177 |
|
|
2020
Q3 | $37K | Sell |
1,444
-188
| -12% | -$11.9K | ﹤0.01% | 10274 |
|
|
2020
Q2 | $119K | Sell |
1,632
-1,260
| -44% | -$87.1K | ﹤0.01% | 9406 |
|
|
2020
Q1 | $152K | Buy |
2,892
+801
| +38% | +$53.5K | ﹤0.01% | 8978 |
|
|
2019
Q4 | $171K | Buy |
2,091
+172
| +9% | +$12.1K | ﹤0.01% | 8868 |
|
|
2019
Q3 | $108K | Buy |
1,919
+742
| +63% | +$55.6K | ﹤0.01% | 9526 |
|
|
2019
Q2 | $141K | Buy |
+1,177
| New | +$197K | ﹤0.01% | 9416 |
|
|
2019
Q1 | – | Sell |
-5,756
| Closed | -$1.03M | – | 8704 |
|
|
2018
Q4 | $1.03M | Buy |
+5,756
| New | +$1.26M | ﹤0.01% | 4612 |
|
|
2018
Q3 | – | Sell |
-1,035
| Closed | -$367K | – | 9083 |
|
|
2018
Q2 | $414K | Buy |
+1,035
| New | +$452K | ﹤0.01% | 7184 |
|
|
2017
Q4 | – | Sell |
-735
| Closed | -$304K | – | 9147 |
|
|
2017
Q3 | $313K | Sell |
735
-24
| -3% | -$6.45K | ﹤0.01% | 7312 |
|
|
2017
Q2 | $121K | Sell |
759
-6,168
| -89% | -$841K | ﹤0.01% | 8596 |
|
|
2017
Q1 | $866K | Buy |
6,927
+3,836
| +124% | +$495K | ﹤0.01% | 5433 |
|
|
2016
Q4 | $375K | Buy |
3,091
+2,013
| +187% | +$315K | ﹤0.01% | 7544 |
|
|
2016
Q3 | $162K | Buy |
+1,078
| New | +$105K | ﹤0.01% | 7726 |
|
Other funds holding ABEO
NCM
ACM
CCC
SCM
VCM
PBM
KCM
Susquehanna International Group's ABEO Position: Q1 2026 in Review
Susquehanna International Group reduced its Abeona Therapeutics (ABEO) stake by 38% in Q1 2026, selling an estimated $1.34M and leaving 432,370 shares worth $1.94M. The position accounts for ﹤0.01% of the portfolio, ranked #6263.
Susquehanna International Group first reported a position in ABEO in Q3 2016 and has held it in 27 quarters since. The position peaked at $3.7M in Q4 2025. 108 funds tracked by Wall St. Rank hold ABEO as of Q1 2026.
- Susquehanna International Group held 432,370 shares of Abeona Therapeutics worth $1.94M as of Q1 2026.
- Susquehanna International Group sold 268,918 Abeona Therapeutics shares in Q1 2026, an estimated $1.34M.
- Abeona Therapeutics made up ﹤0.01% of Susquehanna International Group's portfolio in Q1 2026, its #6263 holding.
- Susquehanna International Group first reported a position in Abeona Therapeutics in Q3 2016 and has held it in 27 quarters since.
- Susquehanna International Group's Abeona Therapeutics position peaked at $3.7M in Q4 2025.
- 108 funds tracked by Wall St. Rank held Abeona Therapeutics as of Q1 2026.
Based on Susquehanna International Group's 13F filing for Q1 2026, filed 15 May 2026.